目的 探讨元胡止痛胶囊联合盐酸洛美利嗪胶囊治疗偏头痛的疗效。方法 选取河北医科大学第三医院在2022年9月—2024年9月收治的偏头痛患者共计120例，按随机数字表法将所有患者分为对照组和治疗组，每组60例。对照组患者口服盐酸洛美利嗪胶囊，2次/d，1粒/次。治疗组患者在对照组治疗的基础上口服元胡止痛胶囊，3次/d，2粒/次。两组患者均持续治疗1个月。对比两组的治疗效果、偏头痛症状、生活质量、脑部血流动力学、血清指标。结果 治疗后，治疗组的总有效率95.00%明显高于对照组的总有效率81.67%，组间差异显著（P＜0.05）。两组治疗后的发作频次、持续时间、视觉模拟量表（VAS）评分均显著降低（P＜0.05）；治疗组治疗后发作频次、持续时间、VAS评分均低于对照组（P＜0.05）。治疗后，两组的偏头痛生活质量问卷（MSQ）评分显著减小（P＜0.05），且治疗组的MSQ评分小于对照组（P＜0.05）。两组治疗后的脑中动脉收缩期峰值速度（Vs）、阻力指数（RI）、搏动指数（PI）均降低（P＜0.05），且治疗组的脑中动脉Vs、RI、PI低于对照组（P＜0.05）。两组治疗后的血清降钙素基因相关肽（CGRP）、环氧合酶-2（COX-2）、基质金属蛋白酶-9（MMP-9）水平均降低（P＜0.05）；治疗组治疗后血清CGRP、COX-2、MMP-9水平低于对照组（P＜0.05）。结论 元胡止痛胶囊联合盐酸洛美利嗪胶囊可提高偏头痛的临床疗效，明显减轻偏头痛症状，提高患者生活质量，改善脑部血流动力学水平，减轻炎症反应。

Objective To explore the efficacy of Yuanhu Zhitong Capsules combined with Lomerizine Hydrochloride Capsules in treatment of migraine. Methods A total of 120 patients admitted to Hebei Medical University Third Hospital from September 2022 to September 2024 were selected, and all patients were randomly divided into control group and treatment group using a random number table method, with 60 patients in each group. Patients in the control group took Lomerizine Hydrochloride Capsules orally, twice daily, 1 capsule/time. Patients in the treatment group took Yuanhu Zhitong Capsules orally on the basis of the control group, 3 times daily, 2 capsules/time. Two groups of patients received continuous treatment for one month. The clinical efficacy, migraine symptoms, quality of life, cerebral hemodynamics, and serum indicators were compared between the two groups. Results After treatment, the total effective rate of the treatment group (95.00%) was significantly higher than 81.67% of the control group, and the difference between the two groups was significant (P < 0.05). After treatment, the frequency, duration, and VAS scores in both groups were significantly decreased (P < 0.05), and the frequency, duration, and VAS scores in the treatment group was lower than that in the control group (P < 0.05). After treatment, the MSQ scores of both groups were significantly decreased (P < 0.05), and the MSQ scores in the treatment group was more obvious lower than those in the control group (P < 0.05). The Vs, RI, and PI of the middle cerebral artery in both groups after treatment were decreased (P < 0.05), and the Vs, RI, and PI of the middle cerebral artery in the treatment group was lower than that in the control group (P < 0.05). The serum levels of CGRP, COX-2, and MMP-9 in both groups after treatment were significantly decreased (P < 0.05). After treatment, the serum levels of CGRP, COX-2 and MMP-9 in the treatment group were lower than those in the control group (P < 0.05). Conclusion: Yuanhuzhitong Capsules combined with Lomerizine Hydrochloride Capsules can improve the efficacy of migraine, significantly relieve migraine symptoms, improve the quality of life of patients, improve cerebral hemodynamics, and reduce inflammatory response.

R971

河北省卫生健康委医学科学研究课题计划（20190082）